Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIa A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder.

NCT00997087 is registered in ClinicalTrials.gov with Parkway Medical Center as lead sponsor.

NCT NCT00997087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00997087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIa A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder.
Lead sponsor
Parkway Medical Center
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2009
Completion date
December 31, 2012
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obsessive compulsive disorder